RxDoctor Payments Data

Miguel Sanchez, MD

Internal Medicine · Miami, FLNPI 1801834650

Payments from drug & device makers

$805in general payments, 2019–2025

Across 16 payments — averaging $50.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$390
  • Abbott$129
  • Novartis$120
  • Sanofi-aventis U.S. LLC$86
  • MML US, Inc.$44
  • Pfizer$13
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$805 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$6,601
Medicare patients
28
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin204$150,455
EliquisApixaban214$147,399
JanuviaSitagliptin Phosphate132$84,609
TrulicityDulaglutide84$79,710
OzempicSemaglutide69$64,475
EntrestoSacubitril/Valsartan71$51,244
TradjentaLinagliptin83$49,191
XareltoRivaroxaban56$46,749
LinzessLinaclotide64$38,180
XifaxanRifaximin11$35,915
FarxigaDapagliflozin Propanediol54$35,524
Lantus SolostarInsulin Glargine,hum.Rec.Anlog313$27,516
JanumetSitagliptin Phos/Metformin Hcl42$25,932
VascepaIcosapent Ethyl49$19,735
MultaqDronedarone Hcl16$17,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$147,399214 claims
Lilly USA, LLCTrulicity$390$79,71084 claims
NovartisEntresto$120$51,24471 claims
AbbVieLinzess, Lumigan$11$45,03491 claims
Sanofi-aventis U.S. LLCMultaq$86$17,97716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →